EMD Serono is the U.S. and Canada healthcare business of Merck KGaA, focused on specialty biopharma conditions such as infertility, multiple sclerosis, and cancer. It operates as part of Merck KGaA rather than an independently listed public company.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07225660 |
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY) |
RECRUITING | NA |
| NCT06518564 |
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer |
RECRUITING | PHASE2 |
| NCT06227949 |
FSH and LH Versus FSH Alone for Ovarian Stimulation in Non-hormone Sensitive Onco-fertility Patients |
NOT_YET_RECRUITING | PHASE3 |
| NCT06138561 |
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments |
RECRUITING | |
| NCT06110195 |
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer |
TERMINATED | PHASE1 |
| NCT06068634 |
Patient-Centered Care Survey |
COMPLETED | |
| NCT04792073 |
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04754542 |
Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study |
COMPLETED | |
| NCT04550455 |
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets |
RECRUITING | PHASE4 |
| NCT04539002 |
Aerobic Exercise for Remyelination in Multiple Sclerosis |
COMPLETED | PHASE1/PHASE2 |
